利妥昔单抗在抗中性粒细胞胞质抗体相关性血管炎治疗中的应用

Rituximab in the treatment of ANCA-associated vasculitides

抗中性粒细胞胞质抗体相关性血管炎(AAV)常累及多个系统,典型的病理改变为寡免疫复合物坏死性血管炎,免疫抑制剂治疗有效,但易复发,长期预后差。利妥昔单抗(RTX)能特异性地清除B淋巴细胞,临床研究显示RTX能有效治疗和预防AAV复发。本文就RTX治疗AAV的作用机制和临床研究进展作一简述。

The anti-neutrophil cytoplasm antibody associated vasculitis （AAV） is a multisystem autoimmune disorders and the typical histopathology is a focal segmental and necrotizing crescentic glomerulonephritis without immunoglobulin deposition in vessel wails. Immunosuppressive therapy has limited efficacy, and most of patients subsequently have a relapse, and poor in long-term prognosis. Rituximab, an anti-CD20 B ceil-depleting therapy, effects on B lymphocytes, and cure AAV. In this paper, we will discuss mechanism of Rituximab action on systemic vasculitis, and summarizes its clinical research progress and value clinical application.